Upcoming webinar: SMA Academy – Hot Topics in Basic SMA Research
NMD4C and Biogen are pleased to invite you to our SMA Academy session on Hot Topics in Basic SMA Research, chaired by NMD4C steering committee member Dr. Rashmi Kothary.
Tuesday, Sept. 22 at 5:00pm ET
The SMA Academy has been developed in partnership with Biogen. The content and design of the presentations are created entirely by the individual speakers, and any potential conflicts of interest will be disclosed. The opinions presented are those of the presenters and are not necessarily those of Biogen Canada Inc.
If you have any questions, please email
Register HERE
Objectives:
- Discuss the latest scientific research on the systemic nature of SMA
- Discuss the role of biomarkers in characterization of SMA severity and response to treatment
- Discuss the metabolic implications of SMA
Topics and speakers:
Lost in translation: The systemic features of SMA
Dr. Marc-Olivier Deguise
Using pre-clinical models to better understand metabolic demands and nutritional support in SMA
Dr. Melissa Bowerman
Biomarkers in SMA
Dr. Robin Parks
Panel discussion led by Dr. Rashmi Kothary
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.